4 Long-Term Survival Results From ESMO 2026 Patients Should Know
Novartis reported 6-year data from the NATALEE trial showing Kisqali (ribociclib) reduced death risk by 19% in early breast cancer. Merck's Keytruda (pembrolizumab) showed 7-year survival benefits in kidney cancer. Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated lasting survival in colorectal cancer. Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations showed 3-year survival gains in stomach/esophageal cancer. All treatments were FDA-approved previously.
How this was made
The 30-second read
Why it matters
These disclosures provide fresh, material information that can shift investor expectations for the involved companies.
Market read
First long‑term efficacy data for approved oncology agents, likely to influence biotech valuations.
What to watch
Potential safety signals over longer horizons and competition from next‑gen therapies could temper upside.
Background
ESMO 2026 presented extended survival data for several FDA‑approved oncology drugs, offering the first multi‑year efficacy readouts.
Ticker impact
Novartis' Kisqali (ribociclib) showed a 19% mortality reduction and 91.9% 6‑year overall survival in the NATALEE trial, the first long‑term data disclosed at ESMO 2026.
likely upward pressure as investors price in durable benefit
First‑time disclosure of statistically meaningful survival benefit; market typically reacts favorably to durable oncology data.
Merck's Keytruda (pembrolizumab) adjuvant data showed 30% lower risk of death and 82.3% 7‑year overall survival versus placebo, presented at ESMO 2026.
potential upward pressure as the indication gains credibility
First long‑term survival readout for an approved indication; investors value durable benefit.
Bristol‑Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) combination achieved 77% 5‑year survival in MSI‑H/dMMR colorectal cancer, disclosed at ESMO 2026.
likely modest upside as the combo's durability is confirmed
First multi‑year survival data for a key immunotherapy combo; market tends to reward durable outcomes.
Jazz Pharmaceuticals' Ziihera (zanidatamab‑hrii) combos showed sustained 3‑year survival (up to 39.8% alive) in HER2‑positive gastroesophageal cancer, presented at ESMO 2026.
potential upward pressure pending market digestion
First long‑term survival results for a newly approved therapy; investors often reward such milestones.
Market effects
reinforces strength of oncology biotech sector with durable trial data
European biotech stocks may see modest gains following the conference
supports broader confidence in immuno‑oncology pipelines worldwide
Counterpoint
Long‑term data may not translate into immediate sales growth; pricing and reimbursement could limit impact.
Key entities
- CompanyNovartis
Pharmaceutical company with Kisqali
- CompanyMerck
Pharma maker of Keytruda
- CompanyBristol‑Myers Squibb
Developer of Opdivo/Yervoy combo
- CompanyJazz Pharmaceuticals
Owner of Ziihera
